Figure 5

CCN6 inhibition enhances the proliferative effects of insulin-like growth factor-1 (IGF-1) on mammary epithelial cells. The bar graph shows that CCN6-deficient cells exhibited a significant increase in bromodeoxyuridine (BrdU) incorporation in response to treatment with IGF-1 (t test, p < 0.03 for both clones). The human mammary epithelial (HME) control cells did not exhibit differences in the S-phase fraction after the addition of IGF-1. The experiment was performed three times independently. Results are expressed as means ± SD for three independent experiments. C1 and C2 are two stable CCN6 deficient clones.